Citation:Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al 2016

Citation

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016 Sep;17(9):1248-60 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27480103.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al 2016	Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?	Meghna Kakani	completed
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al 2016 2	Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?	Cecilia Taing	completed

Compare quality appraisals for each clinical question

• [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|]] (compare critical appraisals)
• [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|]] (compare critical appraisals)

Cited by

1. Targeted therapies for melanoma